LEO Pharma A/S, a global leader in medical dermatology announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA) has adopted a positive opinion and recommended granting a marketing authorization of Adtralza (tralokinumab) for the treatment of moderate-to-severe atopic dermatitis in adult patients who are candidates for systemic therapy.
- Read more about Leo Pharma gets CHMP nod for Adtralza for dermatitis
- Log in or register to post comments
source https://www.pharmatutor.org/pharma-news/2021/leo-pharma-gets-chmp-nod-for-adtralza-for-dermatitis
No comments:
Post a Comment